Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Not yet recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Myeloid 1

Conditions

Leukemia, Myeloid, Acute 8Blastic Plasmacytoid Dendritic Cell Neoplasm 5Precursor Cell Lymphoblastic Leukemia-Lymphoma 2Myelodysplastic Syndromes 2Leukemia, Myelomonocytic, Chronic 2Hematologic Neoplasms 2Recurrence 1Primary Myelofibrosis 1Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 1Pathologic Complete Response 1Neoplasm, Residual 1Myelodysplastic-Myeloproliferative Diseases 1Lymphoma, T-Cell 1Lymphoma, B-Cell 1Leukemia, Biphenotypic, Acute 1Leukemia 1Hodgkin Disease 1Burkitt Lymphoma 1

Interventions

Carboplatin 5pembrolizumab 4Trastuzumab 4Oxaliplatin 4Fluorouracil 4Cyclophosphamide 4Radiotherapy 3Paclitaxel 3Endoscopy 3Docetaxel 3Cytarabine 3Chemoradiotherapy 3Capecitabine 3toripalimab 2Tretinoin 2Surgical Procedures, Operative 2Standard of Care 2Observation 2Neoadjuvant Therapy 2Metformin 2Magnetic Resonance Imaging 2Leucovorin 2Irinotecan 2Immunotherapy 2Immune Checkpoint Inhibitors 2Epirubicin 2Drug Therapy 2Doxorubicin 2Cisplatin 2Blood Specimen Collection 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
OTHER × Pathologic Complete Response × tagraxofusp × Clear all
NCT07007052 2025-11-26

TAGVEN

French Innovative Leukemia Organisation

Phase 2 Not yet recruiting
33 enrolled
Myeloid

Pathologic Complete Response, Blastic Plasmacytoid Dendritic Cell Neoplasm

Data powered by HemOnc (CC BY 4.0) Colophon âš¡